NCT04510181 is a NA clinical trial of amino acid-based blend in Fibromyalgia, sponsored by Pekarovics, Susan, MD.

Who is sponsoring NCT04510181?

NCT04510181 is sponsored by Pekarovics, Susan, MD.

What drugs are being tested in NCT04510181?

Interventions in NCT04510181: amino acid-based blend.

What condition does NCT04510181 study?

NCT04510181 studies Fibromyalgia.

Is NCT04510181 still recruiting?

NCT04510181 is currently status unknown. Last updated 12 August 2020.

Last reviewed 2020-08-12 · How we verify

NCT04510181

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of an Amino-Acid-Based Blend on Human Growth Hormone (hGH) and Fibromyalgia (FM) Symptoms

Status unknown NA Last updated 12 August 2020

What this trial tests

NA trial testing amino acid-based blend in Fibromyalgia in 100 participants. Status unknown.

Timeline

1 August 2020

Primary endpoint
31 July 2022

31 July 2022

Quick facts

Lead sponsor	Pekarovics, Susan, MD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 August 2020
Primary completion	31 July 2022
Estimated completion	31 July 2022
Sites	1 location across United States

Drugs / interventions tested

amino acid-based blend

Conditions studied

Fibromyalgia — all drugs for Fibromyalgia →

Sponsor

Pekarovics, Susan, MD

Who can join

Adults 18 to 80, any sex, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to investigate the effect of the amino acid-based blend on growth hormone levels (measured by IGF-1) and clinical symptoms in individuals with treatment-resistant FM and low-normal hGH.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Stress-associated weight gain, fibromyalgia symptoms, cardiometabolic markers, and human growth hormone suppression respond to an amino acid supplement blend: Results of a prospective, cohort study.
Pekarovics S, Beres A, Kelly C, Billes SK, et al · · 2023 · cited 2× · PMID 36998474 · DOI 10.3389/fendo.2023.1053692

Verify or expand the search:

Other recruiting trials for Fibromyalgia

Currently open trials in the same condition.

NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
NCT07245303 — Neural Mechanisms of Light Driven Analgesia · NA · recruiting
NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
NCT07465991 — The Effect of Digital Cognitive Behavioural Therapy for Insomnia on Physical Activity in Fibromyalgia · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04510181 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pekarovics, Susan, MD
Last refreshed: 12 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04510181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing